KindredBio Announces Initiation of Pivotal Clinical Study for AtoKin™ in Dogs

AtoKin™, KindredBio’s second lead product, is expected to be a major advance in the treatment of symptoms associated with atopic dermatitis.

SAN FRANCISCO, California. (February 20, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-002) in dogs with atopic dermatitis. The trial is being conducted at veterinary sites across the United States and, if positive, is expected to lead to the approval of AtoKin by 2015.

Read more

KindredBio to Present at 2014 Leerink Global Healthcare Conference

SAN FRANCISCO, California. (February 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that members of its senior management team will participate in a fireside chat presentation at the 2014 Leerink Global Healthcare Conference in New York City:

Read more